Haizhen Andrew Zhong, PhD

Associate Professor

  • 793 Citations
  • 16 h-Index
20042019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 2004 2019

  • 793 Citations
  • 16 h-Index
  • 36 Article
  • 4 Review article
  • 2 Chapter
  • 2 Editorial
Filter
Review article
2016
15 Citations (Scopus)

Advances in the development of class I phosphoinositide 3-kinase (PI3K) inhibitors

Sabbah, D. A., Hu, J. & Zhong, H. A., May 1 2016, In : Current Topics in Medicinal Chemistry. 16, 13, p. 1413-1426 14 p.

Research output: Contribution to journalReview article

1-Phosphatidylinositol 4-Kinase
Drug Design
Structure-Activity Relationship
Rheumatoid Arthritis
Cell Survival
2011
37 Citations (Scopus)

Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways

Zhong, H. A. & Phillip Bowen, J., Jun 1 2011, In : Current Topics in Medicinal Chemistry. 11, 12, p. 1571-1590 20 p.

Research output: Contribution to journalReview article

Protein-Tyrosine Kinases
Clinical Trials, Phase I
Renal Cell Carcinoma
Drug Resistance
Non-Small Cell Lung Carcinoma
2007
53 Citations (Scopus)

Molecular design and clinical development of VEGFR kinase inhibitors

Zhong, H. & Bowen, J. P., Jul 1 2007, In : Current Topics in Medicinal Chemistry. 7, 14, p. 1379-1393 15 p.

Research output: Contribution to journalReview article

Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor Receptor-1
Vascular Endothelial Growth Factor Receptor-2
Phosphotransferases
Receptor Protein-Tyrosine Kinases
2006
57 Citations (Scopus)

Antiangiogenesis drug design: Multiple pathways targeting tumor vasculature

Zhong, H. & Bowen, J. P., Apr 1 2006, In : Current medicinal chemistry. 13, 8, p. 849-862 14 p.

Research output: Contribution to journalReview article

Drug Design
Angiogenesis Inhibitors
Blood vessels
Tumors
Blood Vessels